UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9505-9505

2019

Volltextzugriff (PDF)

Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAF V600 -mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERING MELANOMA

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9526-9526

2022

Volltextzugriff (PDF)

Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9568-9568

2021

Volltextzugriff (PDF)

An open-label, uncontrolled, single arm phase II trial of the PI3K inhibitor buparlisib in patients with melanoma brain metastases

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS9595-TPS9595

2017

Volltextzugriff (PDF)

Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.104-104

2022

Volltextzugriff (PDF)

Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrence

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9570-9570

2022

Volltextzugriff (PDF)

Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10011-10011

2020

Volltextzugriff (PDF)

Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9527-9527

2018

Volltextzugriff (PDF)

Methylation among members of the PI3K/AKT/mTOR pathway in melanoma brain and extracerebral metastases

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e21515-e21515

2018

Volltextzugriff (PDF)

Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.6015-6015

2019

Volltextzugriff (PDF)

Vemurafenib and ipilimumab: A promising combination?

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e20075-e20075

2015

Volltextzugriff (PDF)

Porocarcinoma expression of high EGFR levels and sensitivity to EGFR or/and MEK inhibition

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9545-9545

2016

Volltextzugriff (PDF)

BRAF/MEK inhibition in melanoma patients with rare BRAF mutations

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9542-9542

2018

Volltextzugriff (PDF)

Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.9062-9062

2014

Volltextzugriff (PDF)

Quantitative assessment of melanoma spread in sentinel and non-sentinel lymph nodes and survival

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.9082-9082

2014

Volltextzugriff (PDF)

The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e20050-e20050

2013

Volltextzugriff (PDF)

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.8526-8526

2012

Volltextzugriff (PDF)

Patients’ and dermatologists’ preferences in artificial intelligence–driven skin cancer diagnostics: A prospective multicentric survey study

Journal of the American Academy of Dermatology, 2024-08, Vol.91 (2), p.366-370

2024

Volltextzugriff (PDF)

Konjunktivales Melanom: Standardisiertes Vorgehen in Diagnostik, Therapie und Nachsorge

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2018-06, Vol.115 (6), p.489-498

2018

Volltextzugriff (PDF)

Conjunctival melanoma : Standard operating procedures in diagnosis, treatment and follow-up care

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2018-06, Vol.115 (6), p.489-498

2018

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(21)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry

Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAF V600 -mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERING MELANOMA

Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study

An open-label, uncontrolled, single arm phase II trial of the PI3K inhibitor buparlisib in patients with melanoma brain metastases

Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)

Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF V600 -positive melanoma: Interim analysis of the ImmunoCobiVem study

Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrence

Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma

Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study

Methylation among members of the PI3K/AKT/mTOR pathway in melanoma brain and extracerebral metastases

Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC)

Vemurafenib and ipilimumab: A promising combination?

Porocarcinoma expression of high EGFR levels and sensitivity to EGFR or/and MEK inhibition

BRAF/MEK inhibition in melanoma patients with rare BRAF mutations

Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib

Quantitative assessment of melanoma spread in sentinel and non-sentinel lymph nodes and survival

The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases

Patients’ and dermatologists’ preferences in artificial intelligence–driven skin cancer diagnostics: A prospective multicentric survey study

Konjunktivales Melanom: Standardisiertes Vorgehen in Diagnostik, Therapie und Nachsorge

Conjunctival melanoma : Standard operating procedures in diagnosis, treatment and follow-up care

Suchergebnisse filtern